Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291356 · ClinicalTrials.gov registry record · Phase 2
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00291356: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00291356 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00291356, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
Interventions
- DRUG GSK189075 oral tablets
- DRUG GW869682 oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00291356 record still lists
NCT00291356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which GSK189075 oral tablets is the first listed.
NCT00291356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00291356 about?
NCT00291356 is a clinical study titled "GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients". This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
What is the current status of trial NCT00291356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00291356?
The interventions under investigation include: GSK189075 oral tablets (DRUG), GW869682 oral tablets (DRUG).
Who is sponsoring clinical trial NCT00291356?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00291356's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia